PH-ILD – Talk Bio

Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer

8 months ago talkbio0Tagged Bayer, Lung Diseases, Interstitial, Mosliciguat, PH-ILD, Pulmonary Hypertension, Pulmovant, Roivant

Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease

Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity

8 months ago talkbio0Tagged 4-aminohippuric acid, exclusivity, Liquidia, PH-ILD, Pulmonary arterial hypertension, Tentative Approval, Tyvaso, United States Food and Drug Administration, YUTREPIA

Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD

FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease

8 months ago talkbio0Tagged Associated with, Lung Diseases, Interstitial, PH-ILD, Pulmonary arterial hypertension, Pulmonary Hypertension, regulatory exclusivity, Tentative Approval, Tyvaso, United States Food and Drug Administration, United Therapeutics, YUTREPIA

YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso